A Phase I Clinical Study, Randomized, Single-blind,Placebo-controlled, Multiple Doses, Dose Escalation Study fo the Safety, Tolerability and Pharmacokinetics of HX-1171 in Healthy Male Subjects.

Biotoxtech Co., Ltd1 site in 1 countryJune 28, 2013

ConditionsHealthy

DrugsHX-1171

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Healthy
Sponsor: Biotoxtech Co., Ltd
Locations: 1
Status: Temporarily Not Available
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study is designed to multiple dose and dose escalation study

Detailed Description

A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Single Dose Escalation Study of the Safety, Tolerabiluty, and Pharmacokinetics of HX-1171 in Healthy Male Subjects

Registry

clinicaltrials.gov

Start Date

June 28, 2013

End Date

TBD

Last Updated

12 years ago

Study Type

Expanded Access

Sex

Male

Investigators

Sponsor

Biotoxtech Co., Ltd

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Adult males aged 20 to 40 years at screening.
•Be able to comply with the requirement of the study. Subject must provide written informed consent prior to study participation.

Exclusion Criteria

•History or presence of liver, kidney, or nervous system disease, respiratory disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric or gastrointestinal disorders.
•History of known hypersensitivity to drugs including HX-1171.